Vente de participation dans STEM Animal Health Inc.
PARTS DU FNB DESJARDINS IR USA INDICE FAIBLE EN CO2
$37.03
06:35 07/05/24
Groupe Animalcare plc
("Animalcare", the "Company" or the "Group")
Sale of equity in STEM Animal Health Inc. to Dechra Pharmaceuticals Limited
Exclusive Licence and Distribution Agreement for biofilm products enhanced
11 Avril 2024. Animalcare Group plc (AIM: ANCR), the international animal health business, today announces that it has reached agreement in principle to sell its 33.34% equity stake in STEM Animal Health Inc. (STEM) to Dechra Pharmaceuticals Limited ("Dechra") for a total cash payment of US$4.7m, payable upon completion of the transaction. STEM is currently owned by Animalcare and Canada-based Kane Biotech Inc. ("Kane Biotech").
Other items covered by the agreement (the "Agreement") will bring the total potential monetary value of the deal for the Group to approximately US$5.4m. The sale of the minority stake secures a positive return on investment for Animalcare while further strengthening the Group's cash position following the disposal of Identicare announced on 28 February 2024.
STEM was established in September 2020 as a joint venture by Animalcare and Kane Biotech with a focus on treating biofilm-related ailments in animals. Under that agreement, Animalcare was granted rights to commercialise products based on Kane Biotech's coactiv+TM and DispersinB® technology in global veterinary markets outside the Americas.
Under the terms of the Agreement, the existing licence and distribution agreement with STEM will be extended to allow Animalcare access to all channels in Europe and the UK. This means Animalcare can maximise the value of the dental franchise through both veterinary and retail channels including via e-commerce.
In addition, Animalcare will maintain influence over the choice of new product development options associated with the licensed intellectual property through a newly formed joint innovation team with Dechra and Kane Biotech.
Completion of the transaction requires the consent of more than 50% of the shareholders of Kane Biotech.
Chief Executive Officer of Animalcare, Jenny Winter said: "This transaction offers value for Animalcare on several levels. Not only have we secured an attractive return on our equity investment in STEM that adds to our investment firepower, we have gained enhanced commercial licensing rights that grant us more options to reach pet owners in these key markets. Further into the future, I'm also excited about the potential to accelerate development of new biofilm-targeting products by combining the knowledge and resources of all three parties."
À propos de Animalcare
Animalcare Group plc est une organisation internationale de vente et de marketing vétérinaire cotée au Royaume-Uni et cotée à l'AIM. Animalcare est présent dans sept pays et exporte vers environ 40 pays en Europe et dans le monde. Le Groupe se concentre sur la mise sur le marché de produits nouveaux et innovants via son propre pipeline de développement, des partenariats et via des acquisitions.
Pour plus d’informations sur Animalcare, veuillez visiter www.animalcaregroup.com ou communiquez avec:
Groupe Animalcare plc Jenny Winter, Chief Executive Officer Chris Brewster, directeur financier Media/investor relations
| + 44 (0) 1904 487 687
|
Stifel Nicolas Europe Limitée Ben Madison Nick Adams Nick Harland François Nord
| + 44 (0) 20 7710 7600 |
Panmure Gordon (Découper Broker) Corporate Finance Freddy Crossley/Emma Earl Courtage d'entreprise Rupert Deard
| + 44 (0) 20 7886 2500 |
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.